- Início
- Programa
Programa
*Grade poderá sofrer ajustes sem aviso prévio.
| NOVEMBER 1ST | ||
|---|---|---|
| 08:30 | 09:00 | Opening Conference: “Prof Henry H. Neufeld”. Speaker Prof Dr Otavio Berwanger (Executive Director of the George Institute for Global Health and Chair in Clinical Trials at Imperial College London) Modelos Inovadores e Eficientes de Clinical Trials com Intervenções Farmacológicas para Doenças Cardiovasculares |
| Lipid-lowering therapy (Coordinator: Marcelo Bertolami) | ||
| 09:00 | 09:15 | Lipid-lowering targets and therapy in patients with ACS |
| 09:15 | 09:30 | Lipid-lowering targets and therapy in patients with DM |
| 09:30 | 09:45 | What should we do when statins are not enough? |
| 09:45 | 10:00 | Debate |
| 10:00 | 10:30 | Coffee Break |
| 10:30 | 11:30 | Satellite symposium |
| JOINT SESSION ISCP-SIAC | ||
| 11:30 | 11:45 | New strategies for Resistant Hypertension |
| 11:45 | 12:00 | Polypill in Clinical Practice: What are we Waiting For? |
| 12:00 | 12:15 | Familial Hypercholesterolemia, new Opportunities for Difficult Patients |
| 12:15 | 12:30 | Debate: Obesity Life-style modifications: What is the real impact on obesity? Lessons learned with old generations of medications for obesity The impact new generations (GLP-1 agonists and dual GIP/GLP-1 agonisms) on weight and outcomes Pipeline and perpectives for new molecules |
| 12:30 | 13:30 | Lunch and Satellite symposium |
| Hypertension | ||
| 13:30 | 14:30 | Combination of antihypertensive medications |
| 14:30 | 15:30 | Lunch and Satellite symposium |
| 15:30 | 16:00 | Coffee break |
| Heart Failure | ||
| 16:00 | 16:15 | Pharmacological Pillars of HFrEF therapy |
| 16:15 | 16:30 | Pharmacological Pillars of HFmrEF therapy |
| 16:30 | 16:45 | Pharmacological Pillars of HFpEF therapy |
| 16:45 | 17:00 | Debate |
| Multiple Themes: Drugs, Vitamins and hormones | ||
| 17:00 | 17:15 | Does Vitamin D improve cardiometabolic health? |
| 17:15 | 17:30 | Benefits of beta-3 adrenergic agonism on the CV system |
| 17:30 | 17:45 | Cardiovascular disease in transgender individuals |
| 17:45 | 18:00 | Debate |
| Atrial fibrillation | ||
| 18:00 | 18:15 | DOACs use in AF in 2024 |
| 18:15 | 18:30 | Antithrombotic strategies after ACS and AF |
| 18:30 | 18:45 | Reversion or heart rate control in patients with AF? |
| 18:45 | 19:00 | Debate |
| NOVEMBER 2ND | ||
|---|---|---|
| JOINT SESSION ISCP-WHF Pharmacotherapy Potpourri |
||
| 08:30 | 08:45 | HF Prevention, What is in the Horizon? |
| 08:45 | 09:00 | Flu Shot and CV Disease, as Important as Statin? |
| 09:00 | 09:15 | Novel Oral Anticoagulants and Emerging Agents |
| 09:15 | 09:30 | Debate |
| Innovations in vascular ageing and hypertension | ||
| 09:30 | 10:00 | Oscillometric devices for vascular ageing and central blood pressure parameters and evaluation |
| 10:00 | 10:15 | Emerging antihypertensive classes: What can we expect for the future? |
| 10:15 | 10:30 | RNA interference strategies for the treatment of hypertension |
| 10:30 | 11:00 | Coffee Break |
| Inflammation in CVD | ||
| 11:00 | 11:15 | Anti-Inflammatory therapy in atherosclerosis |
| 11:15 | 11:30 | Colchicine in chronic and acute coronary syndromes |
| 11:30 | 11:45 | Anti-Inflammatory therapy in HF |
| 11:45 | 12:00 | Debate |
| 12:00 | 13:00 | Lunch and Satellite symposium |
| Metabolic Associated Fatty Liver Disease (MAFLD) | ||
| 13:00 | 13:15 | How to diagnosis MAFLD |
| 13:15 | 13:30 | MAFLD and CV risk |
| 13:30 | 13:45 | MAFLD therapy |
| 13:45 | 14:00 | Debate |
| Joint Session with SBC | ||
| 14:00 | 14:15 | Dano cerebrovascular e declínio cognitivo: Como avaliar? |
| 14:15 | 14:30 | Polypills in Hypertension |
| 14:30 | 14:45 | Polypills in Heart failure |
| 14:45 | 15:00 | Debate |
| Antithrombotics | ||
| 15:00 | 15:15 | Antithrombotic treatment in patients post TAVR. |
| 15:15 | 15:30 | Bleeding risk and reversers of antithrombotics |
| 15:30 | 15:45 | Warfarin indications in 2024 |
| 15:45 | 16:00 | Debate |
| Cardiomyopathies Therapy | ||
| 16:00 | 16:15 | Hypertrophic cardiomyopathy |
| 16:15 | 16:30 | Amyloidosis |
| 16:30 | 16:45 | Arrhythmogenic dysplasia of the right ventricle |
| 16:45 | 17:00 | Debate |
| Closing Remarks | ||
| 17:00 | 17:30 | Closing remarks |
Português
English